<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>INNOHEP- tinzaparin sodium injection, solution </strong><br>LEO Pharma Inc.<br></p></div>
<h1><span class="Bold">INNOHEP®                              R<span class="Sub">x</span>only
		<br>(tinzaparin sodium injection)</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">For Subcutaneous (SC) Use Only</span></p>
</div>
<div class="Warning">
<a name="s6"></a><a name="section-2"></a><p></p>
<h1>WARNING: SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMAS</span></h1>
<p class="First"><span class="Bold">Epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture.  These <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>.  Consider these risks when scheduling patients for spinal procedures.  Factors that can increase the risk of developing epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> in these patients include:</span></p>
<br><ul>
<li class="Bold">Use of indwelling epidural catheters</li>
<li class="Bold">Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants.</li>
<li class="Bold">A history of traumatic or repeated epidural or spinal punctures</li>
<li class="Bold">A history of <span class="product-label-link" type="condition" conceptid="73302" conceptname="Curvature of spine">spinal deformity</span> or spinal surgery</li>
</ul>
<p><span class="Bold">Monitor patients frequently for signs and symptoms of neurological impairment.  If neurological compromise is noted, urgent treatment is necessary.</span></p>
<p><span class="Bold">Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis (see <a href="#s28">WARNINGS, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>,</a> and <a href="#s36">PRECAUTIONS, Drug Interactions</a>).</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s8"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">INNOHEP® is a sterile solution, containing tinzaparin sodium, a low molecular weight heparin.  It is available in a multiple dose 2 mL vial.
</p>
<p>Each 2 mL vial contains 20,000 anti-Factor Xa IU (anti-Xa) of tinzaparin sodium per mL, for a total of 40,000 IU, and 3.1 mg/mL sodium metabisulfite as a stabilizer. The vial contains 10 mg/mL benzyl alcohol as a preservative.  Sodium hydroxide may be added to achieve a pH range of 5.0 to 7.5.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1 Composition of 20,000 anti-Xa IU/mL INNOHEP® (tinzaparin sodium injection)
</span></caption>
<col align="left" width="52.900%">
<col align="left" width="47.100%">
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Component</span><br>
</th>
<th class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Quantity per mL</span></th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="2" valign="top"><p class="First Footnote"><span class="Sup">1</span> Corresponding to 3.4 mg/mL sodium bisulfite
</p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top">Tinzaparin sodium
</td>
<td class="Botrule Rrule" align="left" valign="top">20,000 anti-Xa IU
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Benzyl alcohol, USP
</td>
<td class="Botrule Rrule" align="left" valign="top">10 mg
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Sodium metabisulfite, USP
</td>
<td class="Botrule Rrule" align="left" valign="top">3.106 mg<span class="Sup">1</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Sodium hydroxide, USP
</td>
<td class="Botrule Rrule" align="left" valign="top">as necessary
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Water for Injection, USP
</td>
<td class="Botrule Rrule" align="left" valign="top">q.s. to 1 mL
</td>
</tr>
</tbody>
</table>
<p>Tinzaparin sodium is the sodium salt of a low molecular weight heparin obtained by controlled enzymatic depolymerization of heparin from porcine intestinal mucosa using heparinase from <span class="Italics">Flavobacterium heparinum</span>.  The majority of the components have a 2-O-sulpho-4-enepyranosuronic acid structure at the non-reducing end and a 2-N,6-O-disulpho-D-glucosamine structure at the reducing end of the chain.
</p>
<p>Potency is determined by means of a biological assay and interpreted by the first International Low Molecular Weight Heparin Standard as units of anti-factor Xa (anti-Xa) activity per milligram.  The mean tinzaparin sodium anti-factor Xa activity is approximately 100 IU per milligram.  The average molecular weight ranges between 5,500 and 7,500 daltons.  The molecular weight distribution is:
</p>
<div class="Figure">
<a name="f1"></a><img alt="Molecular Weight Distribution" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1513b960-d9d1-11de-8a1e-0002a5d5c51b&amp;name=innohep-01.jpg">
</div>
<div class="Figure">
<a name="f2"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1513b960-d9d1-11de-8a1e-0002a5d5c51b&amp;name=innohep-02.jpg"><p class="MultiMediaCaption">Structural Formula
</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s9"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Tinzaparin sodium is a low molecular weight heparin with antithrombotic properties. Tinzaparin sodium inhibits reactions that lead to the clotting of blood including the formation of fibrin clots, both <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span>.  It acts as a potent co-inhibitor of several activated coagulation factors, especially Factors Xa and IIa (thrombin). The primary inhibitory activity is mediated through the plasma protease inhibitor, antithrombin.
</p>
<p><span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">Bleeding time</span> is usually unaffected by tinzaparin sodium. <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">Activated partial thromboplastin time</span> (aPTT) is prolonged by therapeutic doses of tinzaparin sodium used in the treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT).  <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time (PT) may be slightly prolonged with tinzaparin sodium treatment but usually remains within the normal range.  Neither aPTT nor PT can be used for therapeutic monitoring of tinzaparin sodium.
</p>
<p>Neither unfractionated heparin nor tinzaparin sodium have intrinsic fibrinolytic activity; therefore, they do not lyse existing clots.  Tinzaparin sodium induces release of tissue factor pathway inhibitor, which may contribute to the antithrombotic effect.  Heparin is also known to have a variety of actions that are independent of its anticoagulant effects.  These include interactions with endothelial cell growth factors, inhibition of smooth muscle cell proliferation, activation of lipoprotein lipase, suppression of aldosterone secretion, and induction of platelet aggregation.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics/Pharmacodynamics
</h2>
<p class="First">Anti-Xa and anti-IIa activities are the primary biomarkers for assessing tinzaparin sodium exposure because plasma concentrations of low molecular weight heparins cannot be measured directly.  Because of analytical assay limitations, anti-Xa activity is the more widely used biomarker.  The measurements of anti-Xa and anti-IIa activities in plasma serve as surrogates for the concentrations of molecules which contain the high-affinity binding site for antithrombin (anti-Xa and anti-IIa activities).  Monitoring patients based on anti-Xa activity is generally not advised.  The data are provided in <a href="#f3">Figure 1</a> and <a href="#t2">Table 2.</a> below.
</p>
<p>Studies with tinzaparin sodium in healthy volunteers and patients have been conducted with both fixed- and weight-adjusted dose administration.  Recommended therapy with tinzaparin sodium is based on weight-adjusted dosing (see <span class="Bold"><a href="#s56">DOSAGE AND ADMINISTRATION</a></span>).
</p>
<div class="Figure">
<a name="f3"></a><img alt="Figure 1. Mean and Standard Deviation of Anti-Xa Activity Following SC Administration of a Single 4,500 IU* dose and Once Daily Multiple SC Dose of 175 IU/kg Tinzaparin Sodium to Healthy Volunteers" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1513b960-d9d1-11de-8a1e-0002a5d5c51b&amp;name=innohep-03.jpg"><p class="MultiMediaCaption">Figure 1. Mean and Standard Deviation of Anti-Xa Activity Following SC Administration of a Single 4,500 IU* dose and Once Daily Multiple SC Dose of 175 IU/kg Tinzaparin Sodium to Healthy Volunteers
</p>
</div>
<br><a name="t2"></a><table width="100%">
<caption><span>Table 2 Summary of Pharmacokinetic Parameters (Mean and Standard Deviation) Based on Anti-Xa Activity Following Single and Once Daily Multiple Dose SC Administration of Tinzaparin Sodium to Healthy Volunteers
</span></caption>
<col align="left" width="28.268%">
<col align="left" width="30.142%">
<col align="left" width="20.795%">
<col align="left" width="20.795%">
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Parameter (Units)</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Single Dose (N=23)</span></th>
<th class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Multiple Dose (N=14)</span></th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center" valign="top"></th>
<th class="Lrule Rrule Toprule" align="center" valign="top">
<br><span class="Bold">4,500 IU*</span>
</th>
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Day 1</span><br><span class="Bold">(175 IU/kg)</span>
</th>
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Day 5</span><br><span class="Bold">(175 IU/kg)</span>
</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="4" valign="top"><p class="First Footnote">*Dosing based on single dose of 4,500 IU.  Mean dose administered was 64.3 IU/kg.
</p></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top">C<span class="Sub">max</span> (IU/mL)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.25 (0.05)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.87 (0.15)
</td>
<td class="Botrule Rrule" align="center" valign="top">0.93 (0.15)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">T<span class="Sub">max</span> (hr)
</td>
<td class="Botrule Rrule" align="center" valign="top">3.7 (0.9)
</td>
<td class="Botrule Rrule" align="center" valign="top">4.4 (0.7)
</td>
<td class="Botrule Rrule" align="center" valign="top">4.6 (1.0)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">AUC<span class="Sub">0‑∞</span>(IU*hr/mL)
</td>
<td class="Botrule Rrule" align="center" valign="top">2.0 (0.5)
</td>
<td class="Botrule Rrule" align="center" valign="top">9.0 (1.1)
</td>
<td class="Botrule Rrule" align="center" valign="top">9.7 (1.4)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Half-life (hr)
</td>
<td class="Botrule Rrule" align="center" valign="top">3.4 (1.7)
</td>
<td class="Botrule Rrule" align="center" valign="top">3.3 (0.8)
</td>
<td class="Botrule Rrule" align="center" valign="top">3.5 (0.6)
</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="e11"></a><a name="section-3.1.1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-3.1.1.1"></a><p></p>
<h4>Absorption
</h4>
<p class="First">Plasma levels of anti-Xa activity increase in the first 2 to 3 hours following SC injection of tinzaparin sodium and reach a maximum within 4 to 5 hours.  Maximum concentrations (C<span class="Sub">max</span>) of 0.25 and 0.87 IU/mL are achieved following a single SC fixed dose of 4,500 IU (approximately 64.3 IU/kg) and weight-adjusted dose of 175 IU/kg of tinzaparin sodium, respectively.  Based on the extent of absorption (AUC<span class="Sub">0‑∞</span>), a comparison of 4,500 IU and 12,250 IU single doses indicates that increases in anti-Xa activity are greater than dose proportional relative to the increase in dose. Following a single SC injection of tinzaparin sodium, the mean anti-Xa to anti-IIa activity ratio, based on the area under the anti-Xa and anti-IIa time profiles, is 2.8 and is higher than that of unfractionated heparin (approximately 1.2).  The absolute bioavailability (following 4,500 IU SC and intravenous [IV] administrations) is 86.7% based on anti-Xa activity.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-3.1.1.2"></a><p></p>
<h4>Distribution
</h4>
<p class="First">The volume of distribution of tinzaparin sodium ranges from 3.1 L to 5.0 L.  These values are similar in magnitude to blood volume, suggesting that the distribution of anti-Xa activity is limited to the central compartment.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-3.1.1.3"></a><p></p>
<h4>Metabolism
</h4>
<p class="First">Low molecular weight heparins are partially metabolized by desulphation and depolymerization.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-3.1.1.4"></a><p></p>
<h4>Elimination
</h4>
<p class="First">In healthy volunteers, the elimination half-life following SC administration of 4,500 IU or 175 IU/kg tinzaparin sodium is approximately 3-4 hours based on anti-Xa activity. Clearance following IV administration of 4,500 IU tinzaparin sodium is approximately 1.7 L/hr. The primary route of elimination is renal.  Anti-Xa activity did not accumulate with once daily dosing of 175 IU/kg for five days in healthy volunteers. (See <a href="#f3">Figure 1</a> and <a href="#t2">Table 2.</a>)
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-3.1.2"></a><p></p>
<h3>Special Populations
									</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-3.1.2.1"></a><p></p>
<h4>Population Pharmacokinetics
</h4>
<p class="First">Anti-Xa concentrations from approximately 180 patients receiving SC tinzaparin sodium once daily (175 IU/kg body weight) as the treatment of proximal DVT and approximately 240 patients undergoing elective hip replacement surgery receiving SC tinzaparin sodium once daily (~65 IU/kg body weight) were analyzed by population pharmacokinetic methods.  The results indicate that neither age nor gender significantly alter tinzaparin sodium clearance based on anti-Xa activity (see <span class="Bold"><a href="#s34">PRECAUTIONS, General</a></span>).  However, a reduction in tinzaparin sodium clearance was observed in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (reduced calculated creatinine clearance) (see <span class="Bold Italics"><a href="#s17">Special Populations, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></span>).  Weight is also an important factor for the prediction of tinzaparin sodium clearance, consistent with the recommendation that INNOHEP® therapy be based on weight-adjusted dosing (see <span class="Bold"><a href="#s56">DOSAGE AND ADMINISTRATION</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-3.1.2.2"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h4>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-3.1.2.2.1"></a><p></p>
<h5>Population Pharmacokinetics
</h5>
<p class="First">In patients being treated with tinzaparin sodium (175 IU/kg) for DVT, a population pharmacokinetic (PK) analysis determined that tinzaparin sodium clearance based on anti-Xa activity was related to creatinine clearance calculated by the Cockroft Gault equation.  In this PK analysis, a reduction in tinzaparin sodium clearance in moderate (30-50 mL/min) and severe (&lt;30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> was observed.  Patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> exhibited a 24% reduction in tinzaparin sodium clearance relative to patients with normal renal function (&gt;80 mL/min).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-3.1.2.2.2"></a><p></p>
<h5>Hemodialysis Studies
</h5>
<p class="First">In a study of 12 <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span> patients undergoing hemodialysis, anti-Xa clearance was reduced 28%, consistent with estimates from the population PK analyses.  In another study of 6 patients undergoing hemodialysis, the half-life of anti-Xa activity following a single IV dose of 75 IU/kg of tinzaparin sodium on an off-dialysis day was prolonged relative to that for healthy volunteers (5.2 versus 1.6 hours).
</p>
<p>
INNOHEP® may increase the risk for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, compared to unfractionated heparin (UFH), when administered to elderly patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (see
<span class="Bold"><a href="#s27">WARNINGS</a></span>
 and 
<span class="Bold"><a href="#s33">PRECAUTIONS</a></span>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-3.1.2.3"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h4>
<p class="First">No prospective studies have assessed tinzaparin sodium pharmacokinetics or pharmacodynamics in hepatically-impaired patients.  However, the hepatic route is not a major route of elimination of low molecular weight heparins (see <span class="Bold"><a href="#s28">WARNINGS, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-3.1.2.4"></a><p></p>
<h4>Elderly
</h4>
<p class="First">
In a controlled clinical study of elderly patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, more patients died after INNOHEP® therapy, compared to patients who received therapy with UFH (see <span class="Bold"><a href="#s27">WARNINGS</a></span>
 and 
<span class="Bold"><a href="#s33">PRECAUTIONS</a></span>).
</p>
<p>Since renal function declines with age, elimination of tinzaparin sodium may be reduced in elderly patients. In a prospective study of 30 elderly patients [6 men, 24 women; aged 87.0 ± 5.9 years; mean body weight 62.7 ± 14.6 kg; creatinine clearance 40.6 ± 15.3 mL/min (range 20-72)] treated with tinzaparin sodium 175 IU/kg once daily for ten days for acute <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span>, there was no accumulation of anti-Xa activity based on peak anti-Xa activity levels.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-3.1.2.5"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span>
</h4>
<p class="First">Based on the results of a prospective clinical study and the population PK analyses, weight-based dosing is appropriate for heavy/obese patients. Tinzaparin sodium PK parameters based on anti-Xa activity are independent of body weight and body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) when tinzaparin sodium is dosed on a weight basis at 175 IU/kg or 75 IU/kg.  In a prospective study of heavy/obese subjects (101 to 165 kg; BMI 26‑61 kg/m<span class="Sup">2</span>), anti-Xa activity time profiles were similar to those in normal-weight volunteer studies. Data at the 175 IU/kg dose are shown in <a href="#f4">Figure 2</a>. Clinical trial experience is limited in patients with a BMI &gt;40 kg/m<span class="Sup">2</span>.
</p>
<div class="Figure">
<a name="f4"></a><img alt="Figure 2 Mean and Standard Deviation of Anti-Xa Activity Following a Single SC Administration of 175 IU/kg Tinzaparin Sodium to Obese Subjects and Normal-Weight Volunteers" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1513b960-d9d1-11de-8a1e-0002a5d5c51b&amp;name=innohep-04.jpg"><p class="MultiMediaCaption">Figure 2 Mean and Standard Deviation of Anti-Xa Activity Following a Single SC Administration of 175 IU/kg Tinzaparin Sodium to Obese Subjects and Normal-Weight Volunteers
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e22"></a><a name="section-3.1.2.6"></a><p></p>
<h4>Pregnancy
</h4>
<p class="First">The disposition of INNOHEP® was studied in 54 pregnant patients in any trimester.  In this open-label, prospective, dose finding study, those treated with an INNOHEP® dose of 175 IU/kg had similar 24-hour anti-Xa curves at 28 (n=17) and 36 (n=20) weeks gestation.  The 175 IU/kg dose resulted in a mean anti-Xa level of 0.3 to 1.0 IU/mL 4 hours after administration.  Mean anti-Xa levels 4 hours post dose suggest that as pregnancy advances there is no clinically significant decrease in anti-Xa levels.  Pregnancy has little or no influence on the pharmacokinetics of INNOHEP® and no dosing adjustment is needed for pregnancy.  (See <span class="Bold"><a href="#s56">Dosage And Administration</a></span>.)  
</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s23"></a><a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES
					</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-4.1"></a><p></p>
<h2>Treatment of Acute <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> (DVT) With or Without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> (PE)
</h2>
<p class="First">In a randomized, multicenter, double-blind trial INNOHEP® (tinzaparin sodium injection) was compared to unfractionated heparin in 435 hospitalized patients with symptomatic, proximal DVT.  Six percent of the enrolled patients had symptomatic <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> confirmed by segmental or greater lung scan defect.  The study patients ranged in age from 19 to 92 years (mean 61 ± 17 years), 55% were male, 88% were white and 8% black.  Patients received either INNOHEP® SC once daily according to body weight (175 IU/kg) and a placebo IV bolus followed by continuous placebo IV infusion, or unfractionated heparin as an initial IV bolus dose (5,000 IU) followed by continuous IV infusion of unfractionated heparin with the rate adjusted according to the aPTT (1.5 to 2.5 times control value) and a once daily SC placebo injection.  Treatment continued for approximately 6 days, and both treatment groups also received oral warfarin sodium starting on Day 2 which continued to Day 90 with doses titrated to a target INR of 2.0 to 3.0.
</p>
<p>The 90-day cumulative thromboembolic (TE) rate [recurrent DVT or PE] with INNOHEP® was not significantly different than the rate with unfractionated heparin.  The data are provided in <a href="#t3">Table 3.</a></p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3 Efficacy of Once Daily INNOHEP® in the Treatment of Acute <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span>
</span></caption>
<col align="left" width="32.467%">
<col align="left" width="29.867%">
<col align="left" width="37.667%">
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="center" valign="top"></th>
<th class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Dosing Regimen</span></th>
</tr>
<tr>
<th class="Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Indication</span></th>
<th class="Botrule Rrule" align="center" rowspan="2" valign="top">
<span class="Bold">INNOHEP®</span><span class="Sup">1</span><br><span class="Bold">175 IU/kg</span><br><span class="Bold">Once<br>Daily</span><br><span class="Bold">SC</span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Rrule" align="center" rowspan="2" valign="top">
<span class="Bold">Heparin</span><span class="Sup">1</span><br><span class="Bold">5,000 IU Bolus</span><br><span class="Bold">then aPTT Adjusted<br>Continuous Infusion</span><br><span class="Bold">IV</span><br><span class="Bold">n (%)</span>
</th>
</tr>
<tr class="Last"><th class="Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Treatment of Acute DVT</span></th></tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">1</span>  Patients were also treated with warfarin sodium commencing within 24-48 hours of tinzaparin sodium or standard heparin therapy.
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">2</span>  All randomized patients who received at least one dose of active study drug
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">3</span>  TE = <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> (DVT and/or PE)
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">4</span>  The 95% Confidence Interval (CI) for the total TE event rate difference (4.0%) was 0.07%, 8.07%.
</p></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top">Intent to Treat Population<span class="Sup">2</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">												216 (100%)
</td>
<td class="Rrule Toprule" align="center" valign="top">												219 (100%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Patient Outcome at 90 Days
</td>
<td class="Rrule Toprule" align="center" valign="top"></td>
<td class="Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">      Total TE<span class="Sup">3</span> Events
</td>
<td class="Rrule Toprule" align="center" valign="top">6 (2.8%)<span class="Sup">4</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">15 (6.8%)<span class="Sup">4</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">         DVTs
</td>
<td class="Rrule Toprule" align="center" valign="top">3 (1.4%)
</td>
<td class="Rrule Toprule" align="center" valign="top">9 (4.1%)
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left" valign="top">         PEs
</td>
<td class="Rrule Toprule" align="center" valign="top">3 (1.4%)
</td>
<td class="Rrule Toprule" align="center" valign="top">6 (2.7%)
</td>
</tr>
</tbody>
</table>
<p>Mortality with INNOHEP® was 4.6% (10 patients) and with heparin 9.6% (21 patients). The 95% confidence interval (CI) for the mortality difference was 0.16%, 9.76%.
</p>
<p>In a multicenter, open-label, randomized clinical trial INNOHEP® was compared to unfractionated heparin as initial treatment for hospitalized patients with symptomatic PE not requiring thrombolytic therapy, embolectomy, or vena cava interruption.  Patients were excluded if they carried an unusually high risk for thromboembolic and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events or other complications. Of the 608 patients treated, 422 had documented DVT.  Prior to determination of study eligibility and randomization, patients were allowed to receive unfractionated heparin; 78% of the patients received unfractionated heparin at therapeutic doses for up to 24 hours, and an additional 4% received heparin at therapeutic doses for greater than 24 hours.  After randomization, INNOHEP® was administered SC once daily, 175 IU/kg body weight; heparin as an initial IV bolus (50 IU/kg) followed by continuous IV infusion with the rate adjusted according to the aPTT (2 to 3 times control value).  For both groups, treatment continued for approximately 8 days.  All patients also received oral anticoagulant treatment starting in the first 3 days which continued to Day 90.
</p>
<p><span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic events</span> were infrequent for both treatment groups.  No difference was observed between the two treatment groups for incidence of recurrence of <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s25"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">INNOHEP® is indicated for the treatment of acute symptomatic <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> with or without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> when administered in conjunction with warfarin sodium.  The safety and effectiveness of INNOHEP® were established in hospitalized patients.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s26"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">INNOHEP® is contraindicated in patients with active major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, in patients with (or history of) <span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">heparin-induced thrombocytopenia</span>, or in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to tinzaparin sodium.
</p>
<p>Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to heparin, sulfites, benzyl alcohol, or pork products should not be treated with INNOHEP®.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s27"></a><a name="section-7"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First">INNOHEP® is not intended for intramuscular or intravenous administration.
</p>
<p>INNOHEP® cannot be used interchangeably (unit for unit) with heparin or other low molecular weight heparins as they differ in manufacturing process, molecular weight distribution, anti-Xa and anti-IIa activities, units, and dosage.  Each of these medications has its own instructions for use.
</p>
<p><span class="Bold">INNOHEP® should not be used in patients with a history of <span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">heparin-induced thrombocytopenia</span> (see <a href="#s26">CONTRAINDICATIONS</a>).</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="e27"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">Increased Risk for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> in Elderly Patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>:</span> INNOHEP® may increase the risk for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, compared to UFH, when administered to elderly patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.
</p>
<p>
A clinical study compared INNOHEP® (175 IU/kg once daily; N = 269) and UFH (N = 268) in the initial treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) and/or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE) in elderly patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (i.e., patients aged 70 years or older with estimated creatinine clearance of ≤ 30 mL/min or patients aged 75 years or older with estimated creatinine clearance of ≤ 60 mL/min).  Oral anticoagulants were co-administered beginning on Days 1-3 and study treatment was continued for at least five days until the international normalized ratio (INR) was between 2-3 on two successive days; oral anticoagulants were then continued alone and patients were followed until 90 days after the start of treatment.  Overall mortality rates were 6.3% in patients treated with UFH and 11.5% in patients treated with INNOHEP®.  Consider the use of alternatives to INNOHEP® in elderly patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.  
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>:</span>  INNOHEP®, like other anticoagulants, should be used with extreme caution in conditions with increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, such as <span class="product-label-link" type="condition" conceptid="4116649" conceptname="Bacterial endocarditis">bacterial endocarditis</span>; severe <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>; congenital or acquired <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> and <span class="product-label-link" type="condition" conceptid="432595" conceptname="Amyloidosis">amyloidosis</span>; active ulcerative and angiodysplastic gastrointestinal disease; <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span>; shortly after brain, spinal or ophthalmological surgery, or in patients treated concomitantly with platelet inhibitors. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> can occur in any tissue or organ of the body during therapy with INNOHEP®.  <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> in some cases has been reported to result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or permanent <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>.  A hemorrhagic event should be seriously considered in the presence of an unexplained <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in hematocrit, hemoglobin, or blood pressure. If severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> occurs, INNOHEP® should be discontinued.
</p>
<p><span class="Bold">Spinal or <span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">epidural hematomas</span> can occur with the associated use of low molecular weight heparins or heparinoids and spinal/epidural anesthesia or spinal puncture which can result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>.  The risk of these events is higher with the use of post-operative indwelling epidural catheters or with the concomitant use of additional drugs affecting hemostasis such as NSAIDs (see <a href="#s6">boxed WARNING</a> and <a href="#s36">PRECAUTIONS, Drug Interactions</a>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>:</span> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> can occur with the administration of INNOHEP®.
</p>
<p>In clinical studies, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (platelet count &lt;100,000/mm<span class="Sup">3</span> if baseline value ≥150,000/mm<span class="Sup">3</span>, ≥50% decline if baseline &lt;150,000/mm<span class="Sup">3</span>) was identified in 1% of patients given INNOHEP®; severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (platelet count less than 50,000/mm<span class="Sup">3</span>) occurred in 0.13%.
</p>
<p><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> of any degree should be monitored closely.  If the platelet count <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 100,000/mm<span class="Sup">3</span>, INNOHEP® should be discontinued. Cases of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with disseminated <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> also have been observed in clinical practice with heparins, and low molecular weight heparins, including tinzaparin sodium.  Some of these cases were complicated by organ <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> with secondary organ dysfunction or limb <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, and have resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-7.4"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> INNOHEP® contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people.  The overall prevalence of sulfite sensitivity in the general population is unknown, but is probably low.  Sulfite sensitivity is more frequent in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> people than in non-<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> people.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span>:</span>  <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span> has been reported from post-marketing surveillance as a rare occurrence.  In some cases <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span> was required.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-7.6"></a><p></p>
<p class="First"><span class="Bold">Miscellaneous:</span> INNOHEP® multiple dose vial contains benzyl alcohol as a preservative.  The administration of medications containing benzyl alcohol as a preservative to premature neonates has been associated with a fatal “Gasping Syndrome." Because benzyl alcohol may cross the placenta, INNOHEP® preserved with benzyl alcohol should be used with caution in pregnant women only if clearly needed (see <span class="Bold"><a href="#s40">PRECAUTIONS, Pregnancy</a></span>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s33"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS
					</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s34"></a><a name="section-8.1"></a><p></p>
<p class="First"><span class="Bold">General:</span> INNOHEP® should not be mixed with other injections or infusions.
</p>
<p>INNOHEP® should be used with care in patients with a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> diathesis, uncontrolled arterial <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or a history of recent gastrointestinal ulceration, <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">diabetic retinopathy</span>, and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.
</p>
<p>Consistent with expected age-related changes in renal function, elderly patients and patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> may show reduced elimination of tinzaparin sodium. INNOHEP® should be used with care in these patients (see <span class="Bold"><a href="#s27">WARNINGS</a></span> and <span class="Bold"><a href="#s15">CLINICAL PHARMACOLOGY, Special Populations</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s35"></a><a name="section-8.2"></a><p></p>
<p class="First"><span class="Bold">Laboratory Tests:</span> Periodic complete blood counts including platelet count and hematocrit or hemoglobin, and stool tests for occult blood are recommended during treatment with INNOHEP®.  When administered at the recommended doses, routine anticoagulation tests such as <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT) and <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> (aPTT) are relatively insensitive measures of INNOHEP® activity and, therefore, are unsuitable for monitoring.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s36"></a><a name="section-8.3"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions:</span> Because of increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, INNOHEP® should be used with caution in patients receiving oral anticoagulants, platelet inhibitors (e.g., salicylates, dipyridamole, sulfinpyrazone, dextran, NSAIDs including ketorolac tromethamine, ticlopidine, and clopidogrel), and thrombolytics.  If coadministration is essential, close clinical and laboratory monitoring of these patients is advised (see <span class="Bold"><a href="#s35">PRECAUTIONS, Laboratory Tests</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="s37"></a><a name="section-8.4"></a><p></p>
<h2>Laboratory Test Interactions
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-8.4.1"></a><p></p>
<p class="First"><span class="Bold">Elevation of Serum Transaminases:</span> Asymptomatic reversible increases in aspartate (AST [<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>]) and alanine (ALT [SGPT]) aminotransferase levels have occurred in patients during treatment with INNOHEP® (see <span class="Bold"><a href="#s48">ADVERSE REACTIONS, Elevations of Serum Aminotransferases</a></span>). Similar increases in transaminase levels have also been observed in patients and volunteers treated with heparin and other low molecular weight heparins.
</p>
<p>Since aminotransferase determinations are important in the differential diagnosis of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, liver disease, and pulmonary emboli, elevations that might be caused by drugs like INNOHEP® should be interpreted with caution.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s39"></a><a name="section-8.5"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span> No long-term studies in animals have been performed to evaluate the carcinogenic potential of tinzaparin sodium.
</p>
<p>Tinzaparin sodium displayed no genotoxic potential in an <span class="Italics">in vitro</span> bacterial cell mutation assay (AMES test), <span class="Italics">in vitro</span> Chinese hamster ovary cell forward gene mutation test, <span class="Italics">in vitro</span> human lymphocyte chromosomal aberration assay, and <span class="Italics">in vivo</span> mouse micronucleus assay.  Tinzaparin sodium at SC doses up to 1800 IU/kg/day in rats (about 2 times the maximum recommended human dose based on body surface area) was found to have no effect on fertility and reproductive performance.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s40"></a><a name="section-8.6"></a><p></p>
<h2>Pregnancy
							</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-8.6.1"></a><p></p>
<h3>Pregnancy:  Category B:
</h3>
<p class="First">											All pregnancies have a background risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, loss, or other adverse outcome regardless of drug exposure.  The fetal risk summary below describes the potential of INNOHEP® to increase the risk of developmental abnormalities above background risk.  
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e41"></a><a name="section-8.6.2"></a><p></p>
<h3>Fetal Risk Summary
</h3>
<dl class="Disc">
<dt> </dt>
<dd><p class="First">INNOHEP® is not predicted to increase the risk of developmental abnormalities.  INNOHEP® does not cross the placenta, based on human and animal studies, and shows no evidence of teratogenic effects or fetotoxicity.  
</p></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-8.6.3"></a><p></p>
<h3>Clinical Considerations
</h3>
<dl class="Disc">
<dt> </dt>
<dd><p class="First">Pregnancy alone confers an increased risk for <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> that is even higher for women with preexisting thromboembolic disease, certain high risk pregnancy conditions, and a history of complications during a previous pregnancy. 
</p></dd>
<dt> </dt>
<dd><p class="First">All patients receiving anticoagulants such as tinzaparin, including pregnant women, are at risk for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.  Pregnant women receiving tinzaparin should be carefully monitored for evidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or excessive anticoagulation.  <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> can occur at any site and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of mother and/or fetus.  Pregnant women should be apprised of the potential hazard to the fetus and the mother if tinzaparin is administered during pregnancy.  Consideration for use of a shorter acting agent should be specifically addressed as delivery approaches.  
 
</p></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e42"></a><a name="section-8.6.4"></a><p></p>
<h3>Data
</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="e43"></a><a name="section-8.6.4.1"></a><p></p>
<dl class="Disc">
<dt> </dt>
<dd><p class="First"><span class="Underline">Human Data</span> - Fifty-four women pregnant or planning to become pregnant with conditions requiring anticoagulation received INNOHEP® in an open-label, prospective, pregnancy dose finding study.  (See <span class="Bold"><a href="#e22">Clinical Pharmacology, Special Populations, Pregnancy.</a></span>)  Patients received 50 to 175 IU/kg/day, with dosing starting as early as prior to conception or as late as 32 weeks gestation.  Duration of exposure ranged from 3 to 463 days (median 159 days).  From 55 pregnancies, there were 50 live births, 3 first trimester <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriages</span>, and 2 intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> at 17 and 30 weeks.  Approximately 6% of pregnancies were complicated by <span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">fetal distress</span>.
</p></dd>
<dt> </dt>
<dd><p class="First">Approximately 10% of pregnant women receiving INNOHEP® experienced significant <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.  A cause and effect relationship for the above observations has not been established.
</p></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e44"></a><a name="section-8.6.4.2"></a><p></p>
<dl class="Disc">
<dt> </dt>
<dd><p class="First"><span class="Underline">Animal Data</span> - <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies have been performed in rats at SC doses up to 1800 IU/kg/day (about 2 times the maximum recommended human dose based on body surface area) and in rabbits at SC doses up to 1900 IU/kg/day (about 4 times the maximum recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to tinzaparin sodium.  There are, however, no adequate and well-controlled studies in pregnant women.  Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.  INNOHEP® does not cross the placenta. 
</p></dd>
</dl>
<p class="First">Cases of "<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Gasping</span> Syndrome" have occurred in premature infants when large amounts of benzyl alcohol have been administered (99 - 404 mg/kg/day).  The 2 mL vial of INNOHEP® contains 20 mg of benzyl alcohol (10 mg of benzyl alcohol per mL) (see <span class="Bold"><a href="#s32">WARNINGS, Miscellaneous</a></span>).  If INNOHEP® is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of potential hazards to the fetus.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s43"></a><a name="section-8.7"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> In studies where tinzaparin sodium was administered subcutaneously to lactating rats, very low levels of tinzaparin sodium were found in breast milk.  It is not known whether tinzaparin sodium is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when INNOHEP® is administered to nursing women.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s44"></a><a name="section-8.8"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> Safety and effectiveness of tinzaparin sodium in pediatric patients have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s45"></a><a name="section-8.9"></a><p></p>
<p class="First"><span class="Bold">Geriatric Use:</span> INNOHEP® may increase the risk for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, compared to UFH, when administered to elderly patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (see <span class="Bold"><a href="#s27">WARNINGS</a></span>
 and 
<span class="Bold"><a href="#s33">PRECAUTIONS</a></span>).
</p>
<p>
In the clinical studies for the treatment of DVT described in the <span class="Bold"><a href="#s23">CLINICAL STUDIES</a></span> section, 58% of patients were 65 or older and 29% were 75 and over. In these studies, no significant overall differences in safety or effectiveness were observed between these subjects and younger subjects.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s46"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS
					</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="e46"></a><a name="section-9.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span>: <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> is the most common adverse event associated with INNOHEP® (tinzaparin sodium injection); however, the incidence of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is low.  In clinical trials, the definition of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> included <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> accompanied by ≥2 gram/dL decrease in hemoglobin, requiring transfusion of 2 or more units of blood products, or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> which was intracranial, retroperitoneal, or into a major prosthetic joint.  The data are provided in <a href="#t4">Table 4.</a></p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4 Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events<span class="Sup">1</span> in Treatment of Acute <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> With or Without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span>
</span></caption>
<col align="left" width="42.619%">
<col align="left" width="25.958%">
<col align="left" width="31.423%">
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Indication</span></th>
<th class="Rrule Toprule" align="center" colspan="2" valign="middle">
<span class="Bold">Treatment Group</span><span class="Sup">1</span>
</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Treatment of Acute DVT</span><br><span class="Bold">With or Without PE</span><br>
</th>
<th class="Rrule Toprule" align="center" valign="top">
<span class="Bold">INNOHEP®</span><br><span class="Bold">N=519</span><br><span class="Bold">%</span>
</th>
<th class="Rrule Toprule" align="center" valign="top">
<span class="Bold">Heparin</span><br><span class="Bold">N=524</span><br><span class="Bold">%</span>
</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">1</span> INNOHEP® 175 IU/kg once daily SC.  Unfractionated heparin initial IV bolus of 5,000 IU followed by continuous IV infusion adjusted to an aPTT of 1.5 to 2.5 or initial IV bolus of 50 IU/kg followed by continuous IV infusion adjusted to an aPTT of 2.0 to 3.0. In all groups treatment continued for approximately 6 to 8 days, and all patients received oral anticoagulant treatment commencing in the first 2 to 3 days.
</p></td></tr>
<tr><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">2</span> <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> accompanied by ≥2 gram/dL decline in hemoglobin, requiring transfusion of 2 or more units of blood products, or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> which was intracranial, retroperitoneal, or into a major prosthetic joint.
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">3</span> The 95% CI on the difference in major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event rates (1.9%) was 0.33%, 3.47%.
</p></td></tr>
</tfoot>
<tbody><tr class="First Last">
<td class="Lrule Rrule Toprule" align="left" valign="middle">Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events<span class="Sup">2</span>
</td>
<td class="Rrule Toprule" align="center" valign="middle">0.8<span class="Sup">3</span>
</td>
<td class="Rrule Toprule" align="center" valign="middle">2.7<span class="Sup">3</span>
</td>
</tr></tbody>
</table>
<p>Fatal or nonfatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> from any tissue or organ can occur.  The signs, symptoms, and severity will vary according to the location and degree or extent of the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.  Hemorrhagic complications may present as, but are not limited to, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, chest, abdomen, joint, muscle or other <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, difficult breathing or swallowing; <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>; <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.  Therefore, the possibility of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> should be considered in evaluating the condition of any anticoagulated patient with complaints which do not indicate an obvious diagnosis (see <span class="Bold"><a href="#s28">WARNINGS, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-9.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span>: In clinical studies <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> was identified in 1% of patients treated with INNOHEP®.  Severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (platelet count &lt;50,000/mm<span class="Sup">3</span>) occurred in 0.13% (see <span class="Bold"><a href="#s29">WARNINGS, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-9.3"></a><p></p>
<p class="First"><span class="Underline">Elevations of Serum Aminotransferases</span>: Asymptomatic increases in aspartate (AST [<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>]) and/or alanine (ALT [SGPT]) aminotransferase levels greater than 3 times the upper limit of normal of the laboratory reference range have been reported in up to 8.8% and 13% for AST and ALT, respectively, of patients receiving tinzaparin sodium for the treatment of DVT. Similar increases in aminotransferase levels have also been observed in patients and healthy volunteers treated with heparin and other low molecular weight heparins.  Such elevations are reversible and are rarely associated with increases in bilirubin (see <span class="Bold"><a href="#s35">PRECAUTIONS, Laboratory Tests</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-9.4"></a><p></p>
<p class="First"><span class="Underline">Local Reactions</span>: Mild local irritation, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, and <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span> may follow SC injection of INNOHEP®.  Injection site <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> has been reported in approximately 16% of patients treated with INNOHEP®.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-9.5"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span>: Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur in association with INNOHEP® use (see <span class="Bold"><a href="#s26">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#s27">WARNINGS</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-9.6"></a><p></p>
<p class="First"><span class="Underline">Adverse Events</span>: Adverse events with INNOHEP® or heparin reported at a frequency of ≥1% in clinical trials with patients undergoing treatment for proximal DVT with or without PE, are provided in <a href="#t5">Table 5.</a></p>
<a name="t5"></a><table width="100%">
<caption><span>Table 5 Adverse Events Occurring in ≥ 1% in Treatment of Acute <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> With or Without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> Studies
</span></caption>
<col align="left" width="42.314%">
<col align="left" width="28.843%">
<col align="left" width="28.843%">
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="center" valign="top"></th>
<th class="Rrule Toprule" align="center" colspan="2" valign="middle">
<span class="Bold">Treatment Group</span><span class="Sup">1</span>
</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center" valign="top">
<br><span class="Bold">Adverse Events</span>
</th>
<th class="Rrule Toprule" align="center" valign="top">
<br><span class="Bold">INNOHEP®</span><br><span class="Bold">N=519</span><br><span class="Bold">n (%)</span>
</th>
<th class="Rrule Toprule" align="center" valign="top">
<br><span class="Bold">Heparin</span><br><span class="Bold">N=524</span><br><span class="Bold">n (%)</span>
</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote">NOS = not otherwise specified
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">1</span> INNOHEP® 175 IU/kg once daily SC.  Unfractionated heparin initial IV bolus of 5,000 IU followed by continuous IV infusion adjusted to an aPTT of 1.5 to 2.5 or initial IV bolus of 50 IU/kg followed by continuous IV infusion adjusted to an aPTT of 2.0 to 3.0. In all groups treatment continued for approximately 6 to 8 days, and all patients received oral anticoagulant treatment commencing in the first 2 to 3 days.
</p></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">19 (3.7%)
</td>
<td class="Rrule Toprule" align="center" valign="top">18 (3.4%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">12 (2.3%)
</td>
<td class="Rrule Toprule" align="center" valign="top">12 (2.3%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">12 (2.3%)
</td>
<td class="Rrule Toprule" align="center" valign="top">8 (1.5%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">10 (1.9%)
</td>
<td class="Rrule Toprule" align="center" valign="top">7 (1.3%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">9 (1.7%)
</td>
<td class="Rrule Toprule" align="center" valign="top">9 (1.7%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">9 (1.7%)
</td>
<td class="Rrule Toprule" align="center" valign="top">10 (1.9%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage NOS</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">8 (1.5%)
</td>
<td class="Rrule Toprule" align="center" valign="top">23 (4.4%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">8 (1.5%)
</td>
<td class="Rrule Toprule" align="center" valign="top">2 (0.4%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">8 (1.5%)
</td>
<td class="Rrule Toprule" align="center" valign="top">11 (2.1%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">8 (1.5%)
</td>
<td class="Rrule Toprule" align="center" valign="top">7 (1.3%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">7 (1.3%)
</td>
<td class="Rrule Toprule" align="center" valign="top">9 (1.7%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">6 (1.2%)
</td>
<td class="Rrule Toprule" align="center" valign="top">8 (1.5%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">6 (1.2%)
</td>
<td class="Rrule Toprule" align="center" valign="top">9 (1.7%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">5 (1.0%)
</td>
<td class="Rrule Toprule" align="center" valign="top">8 (1.5%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">5 (1.0%)
</td>
<td class="Rrule Toprule" align="center" valign="top">6 (1.1%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">4 (0.8%)
</td>
<td class="Rrule Toprule" align="center" valign="top">6 (1.1%)
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">3 (0.6%)
</td>
<td class="Rrule Toprule" align="center" valign="top">7 (1.3%)
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>
</td>
<td class="Rrule Toprule" align="center" valign="top">0
</td>
<td class="Rrule Toprule" align="center" valign="top">7 (1.3%)
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-9.7"></a><p></p>
<p class="First"><span class="Underline">Other Adverse Events in Completed or Ongoing Trials</span>: Other adverse events reported at a frequency of ≥1% in 4,000 patients who received INNOHEP® in completed or ongoing clinical trials are listed by body system:
</p>
<p><span class="Bold Italics">Body as a Whole:</span> injection site <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, reaction unclassified.
</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>, General:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.
</p>
<p><span class="Bold Italics">Central and Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.
</p>
<p><span class="Bold Italics">Gastrointestinal System Disorders:</span> <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span> (not otherwise specified), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>.
</p>
<p><span class="Bold Italics">Heart Rate and Rhythm Disorders:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.
</p>
<p><span class="Bold Italics">Myo-, Endo-, Pericardial and Valve Disorders:</span> <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>.
</p>
<p><span class="Bold Italics">Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Clotting Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.
</p>
<p><span class="Bold Italics">Psychiatric Disorders:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.
</p>
<p><span class="Bold Italics">Red Blood Cell Disorders:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.
</p>
<p><span class="Bold Italics">Resistance Mechanism Disorders:</span> <span class="product-label-link" type="condition" conceptid="4304198" conceptname="Impaired tissue repair">healing impaired</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.
</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorder</span>.
</p>
<p><span class="Bold Italics">Skin and Appendages Disorders:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruption</span>, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>.
</p>
<p><span class="Bold Italics">Urinary System Disorders:</span> <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>.
</p>
<p><span class="Bold Italics">Vascular (Extracardiac) Disorders:</span> <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">thrombophlebitis deep</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">thrombophlebitis leg deep</span>.
</p>
<p>Serious adverse events reported in clinical trials or from post-marketing experience are included in <a href="#t6">Tables 6</a> and <a href="#t7">7</a>, respectively:
</p>
<a name="t6"></a><table width="100%">
<caption><span>Table 6 Serious Adverse Events Associated With INNOHEP® in Clinical Trials
</span></caption>
<col align="left" width="40.000%">
<col align="left" width="60.000%">
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="left" valign="top">
<br><span class="Bold">Category</span>
</th>
<th class="Rrule Toprule" align="left" valign="top">
<br><span class="Bold">Serious Adverse Event</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>-related
</td>
<td class="Rrule Toprule" align="left" valign="top">Anorectal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span><br>Cerebral/intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span><br><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span><br><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal hemorrhage</span><br><span class="product-label-link" type="condition" conceptid="76784" conceptname="Hemarthrosis">Hemarthrosis</span><br><span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">Hematemesis</span><br><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span><br><span class="product-label-link" type="condition" conceptid="258449" conceptname="Hemopericardium">Hemopericardium</span><br><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage NOS</span><br><span class="product-label-link" type="condition" conceptid="4316205" conceptname="Injection site hemorrhage">Injection site bleeding</span><br><span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">Melena</span><br><span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">Purpura</span><br>Retroperitoneal/intra-abdominal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span><br><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal hemorrhage</span><br><span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Organ dysfunction
</td>
<td class="Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina pectoris</span><br><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac arrhythmia</span><br><span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">Dependent edema</span><br><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>/<span class="product-label-link" type="condition" conceptid="4134723" conceptname="Coronary artery thrombosis">coronary thrombosis</span><br><span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Fetal/neonatal
</td>
<td class="Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Congenital anomaly</span><br><span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">Fetal death</span><br><span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">Fetal distress</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Cutaneous
</td>
<td class="Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">Bullous eruption</span><br>Erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span><br><span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">Maculopapular rash</span><br><span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">Skin necrosis</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Hematologic
</td>
<td class="Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">Granulocytopenia</span><br><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>
</td>
<td class="Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span>
</td>
<td class="Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left" valign="top">Neoplastic
</td>
<td class="Rrule Toprule" align="left" valign="top">Neoplasm
</td>
</tr>
</tbody>
</table>
<a name="t7"></a><table width="100%">
<caption><span>Table 7 Other Serious Adverse Events Associated With INNOHEP® from Post-Marketing Surveillance
</span></caption>
<col align="left" width="40.000%">
<col align="left" width="60.000%">
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="left" valign="top">
<br><span class="Bold">Category</span>
</th>
<th class="Rrule Toprule" align="left" valign="top">
<br><span class="Bold">Serious Adverse Event</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top">Organ dysfunction
</td>
<td class="Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">Cholestatic hepatitis</span><br>Increase in hepatic enzymes<br><span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">Peripheral ischemia</span><br><span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>-related
</td>
<td class="Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span><br><span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">Hemoptysis</span><br><span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">Ocular hemorrhage</span><br><span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">Rectal bleeding</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Cutaneous reactions
</td>
<td class="Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4142366" conceptname="Ten">Epidermal necrolysis</span><br>Ischemic <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span><br><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span><br><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Hematologic
</td>
<td class="Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span><br><span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span><br><span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">Thrombocythemia</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reactions</span>
</td>
<td class="Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span><br><span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">Necrosis</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>
</td>
<td class="Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4101602" conceptname="Henoch-Schonlein purpura">Allergic purpura</span><br><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Fetal/neonatal
</td>
<td class="Rrule Toprule" align="left" valign="top">Cutis <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> of the scalp<br>Neonatal <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left" valign="top">General
</td>
<td class="Rrule Toprule" align="left" valign="top">Acute <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">febrile reaction</span>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-9.8"></a><p></p>
<p class="First"><span class="Underline">Ongoing Safety Surveillance</span>:  When neuraxial anesthesia (epidural/spinal anesthesia) or spinal puncture is employed, patients anticoagulated or scheduled to be anticoagulated with low molecular weight heparins or heparinoids for prevention of thromboembolic complications are at risk of developing an epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> which can result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> (see <span class="Bold"><a href="#s6">boxed WARNING</a></span>).
</p>
<p><span class="product-label-link" type="condition" conceptid="45766652" conceptname="Spinal epidural hematoma">Spinal epidural hematoma</span> in association with neuraxial anesthesia or spinal puncture with INNOHEP® has been reported.
</p>
<p><span class="product-label-link" type="condition" conceptid="45766652" conceptname="Spinal epidural hematoma">Spinal epidural hematoma</span> with INNOHEP® administered at a therapeutic dose has been reported in at least one patient who had not received neuraxial anesthesia or spinal puncture.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s54"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE
					</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">Symptoms/Treatment:</span> Accidental overdosage of INNOHEP® (tinzaparin sodium injection) may lead to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications (see <span class="Bold"><a href="#s28">WARNINGS, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></a></span>).  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Nosebleeds</span>, <span class="product-label-link" type="condition" conceptid="437038" conceptname="Blood in urine">blood in urine</span> or <span class="product-label-link" type="condition" conceptid="4103703" conceptname="Melena">tarry stools</span> may be noted as the first signs of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or petechial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span> may precede frank <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. In case of minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, the patient should be monitored for signs of more severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.
</p>
<p>Of patients known to have received an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of tinzaparin sodium in clinical trials, defined as one or more doses &gt;200 IU/kg for the treatment of DVT or &gt;100 IU/kg for the prevention of DVT, approximately 16% experienced a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complication.
</p>
<p>Of spontaneous reports of probable overdosing with tinzaparin sodium, approximately 81% were accompanied by <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, usually <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>.  Most patients who have <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications while receiving INNOHEP® can be controlled by discontinuing INNOHEP®, applying pressure to the site, if possible, and replacing volume and hemostatic blood elements (e.g., red blood cells, fresh frozen plasma, platelets) as required.  In the event that this is ineffective, protamine sulfate can be administered.
</p>
<p>In cases of serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, protamine sulfate (1% solution) can be given by slow IV infusion at a dose of 1 mg protamine for every 100 anti-Xa IU of INNOHEP® given. A second infusion of 0.5 mg protamine sulfate per 100 anti-Xa IU of INNOHEP® may be administered if the aPTT measured 2 to 4 hours after the first infusion remains prolonged.  Even with the additional dose of protamine, the aPTT may remain more prolonged than would usually be found following administration of protamine to reverse unfractionated heparin.  Protamine does not completely neutralize tinzaparin sodium anti-Xa activity (maximum about 60%).
</p>
<p>Particular care should be taken to avoid overdosage with protamine sulfate.  Administration of protamine sulfate can cause severe hypotensive and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>.  Because fatal reactions have been reported with protamine sulfate, it should be given only when resuscitation facilities are readily available. For additional information consult the labeling of Protamine Sulfate Injection, USP, products.
</p>
<p>Single SC doses of tinzaparin sodium at 22,000 and 7,700 IU/kg (about 10 and 7 times the maximum recommended human dose, respectively, based upon body surface area) were lethal to mice and rats, respectively.  Symptoms of acute toxicity included <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> formation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> at the injection site, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, decreased motor activity, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">unsteady gait</span>, <span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">piloerection</span>, and <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s56"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">All patients should be evaluated for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders before administration of INNOHEP®. Since coagulation parameters are unsuitable for monitoring INNOHEP® activity, routine monitoring of coagulation parameters is not required (see <span class="Bold"><a href="#s35">PRECAUTIONS, Laboratory Tests</a></span>).
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-11.1"></a><p></p>
<h2>Adult Dosage
</h2>
<p class="First">The recommended dose of INNOHEP® for the treatment of DVT with or without PE is 175 anti-Xa IU/kg of body weight, administered SC once daily for at least 6 days and until the patient is adequately anticoagulated with warfarin (INR at least 2.0 for two consecutive days).  Warfarin sodium therapy should be initiated when appropriate (usually within 1-3 days of INNOHEP® initiation). Pregnancy has little or no influence on the pharmacokinetics of INNOHEP® and no dosing adjustment is needed for pregnancy. 
</p>
<p>As INNOHEP® may theoretically affect the PT/INR, patients receiving both INNOHEP® and warfarin should have blood for PT/INR determination drawn just prior to the next scheduled dose of INNOHEP®.
</p>
<p><a href="#t8">Table 8</a> provides INNOHEP® doses for the treatment of DVT with or without PE.  It is necessary to calculate the appropriate INNOHEP® dose for patient weights not displayed in <a href="#t8">Table 8</a>.
</p>
<p>An appropriately calibrated syringe should be used to assure withdrawal of the correct volume of drug from INNOHEP® vials.
</p>
<a name="t8"></a><table width="100%">
<caption><span>Table 8  INNOHEP® Weight-based Dosing for Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> With or Without Symptomatic <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span>
</span></caption>
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" valign="top"></th>
<th class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">DVT Treatment</span></th>
<th class="Lrule Rrule" align="center" valign="top"></th>
</tr>
<tr>
<th class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">
<span class="Bold">Patient Body</span><br><span class="Bold">Weight in</span><br><span class="Bold">Pounds</span><br><br>
</th>
<th class="Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">175 IU/kg SC Once Daily</span><br><span class="Bold">20,000 IU per mL</span><br>
</th>
<th class="Botrule Rrule Toprule" align="center" rowspan="2" valign="top">
<span class="Bold">Patient Body</span><br><span class="Bold">Weight in<br>Kilograms</span><br><br>
</th>
</tr>
<tr class="Last">
<th class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Dose</span><br><span class="Bold">(IU)</span>
</th>
<th class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Amount</span><br><span class="Bold">(mL)</span>
</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="center" valign="top">68-80
</td>
<td class="Rrule Toprule" align="center" valign="top">6,000
</td>
<td class="Rrule Toprule" align="center" valign="top">0.3
</td>
<td class="Rrule Toprule" align="center" valign="top">31-36
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">81-94
</td>
<td class="Rrule Toprule" align="center" valign="top">7,000
</td>
<td class="Rrule Toprule" align="center" valign="top">0.35
</td>
<td class="Rrule Toprule" align="center" valign="top">37-42
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">95-107
</td>
<td class="Rrule Toprule" align="center" valign="top">8,000
</td>
<td class="Rrule Toprule" align="center" valign="top">0.4
</td>
<td class="Rrule Toprule" align="center" valign="top">43-48
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">108-118
</td>
<td class="Rrule Toprule" align="center" valign="top">9,000
</td>
<td class="Rrule Toprule" align="center" valign="top">0.45
</td>
<td class="Rrule Toprule" align="center" valign="top">49-53
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">119-131
</td>
<td class="Rrule Toprule" align="center" valign="top">10,000
</td>
<td class="Rrule Toprule" align="center" valign="top">0.5
</td>
<td class="Rrule Toprule" align="center" valign="top">54-59
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">132-144
</td>
<td class="Rrule Toprule" align="center" valign="top">11,000
</td>
<td class="Rrule Toprule" align="center" valign="top">0.55
</td>
<td class="Rrule Toprule" align="center" valign="top">60-65
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">145-155
</td>
<td class="Rrule Toprule" align="center" valign="top">12,000
</td>
<td class="Rrule Toprule" align="center" valign="top">0.6
</td>
<td class="Rrule Toprule" align="center" valign="top">66-70
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">156-168
</td>
<td class="Rrule Toprule" align="center" valign="top">13,000
</td>
<td class="Rrule Toprule" align="center" valign="top">0.65
</td>
<td class="Rrule Toprule" align="center" valign="top">71-76
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">169-182
</td>
<td class="Rrule Toprule" align="center" valign="top">14,000
</td>
<td class="Rrule Toprule" align="center" valign="top">0.7
</td>
<td class="Rrule Toprule" align="center" valign="top">77-82
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">183-195
</td>
<td class="Rrule Toprule" align="center" valign="top">15,000
</td>
<td class="Rrule Toprule" align="center" valign="top">0.75
</td>
<td class="Rrule Toprule" align="center" valign="top">83-88
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">196-206
</td>
<td class="Rrule Toprule" align="center" valign="top">16,000
</td>
<td class="Rrule Toprule" align="center" valign="top">0.8
</td>
<td class="Rrule Toprule" align="center" valign="top">89-93
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">207-219
</td>
<td class="Rrule Toprule" align="center" valign="top">17,000
</td>
<td class="Rrule Toprule" align="center" valign="top">0.85
</td>
<td class="Rrule Toprule" align="center" valign="top">94-99
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">220-232
</td>
<td class="Rrule Toprule" align="center" valign="top">18,000
</td>
<td class="Rrule Toprule" align="center" valign="top">0.9
</td>
<td class="Rrule Toprule" align="center" valign="top">100-105
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">233-243
</td>
<td class="Rrule Toprule" align="center" valign="top">19,000
</td>
<td class="Rrule Toprule" align="center" valign="top">0.95
</td>
<td class="Rrule Toprule" align="center" valign="top">106-110
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">244-256
</td>
<td class="Rrule Toprule" align="center" valign="top">20,000
</td>
<td class="Rrule Toprule" align="center" valign="top">1
</td>
<td class="Rrule Toprule" align="center" valign="top">111-116
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">257-270
</td>
<td class="Rrule Toprule" align="center" valign="top">21,000
</td>
<td class="Rrule Toprule" align="center" valign="top">1.05
</td>
<td class="Rrule Toprule" align="center" valign="top">117-122
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">271-283
</td>
<td class="Rrule Toprule" align="center" valign="top">22,000
</td>
<td class="Rrule Toprule" align="center" valign="top">1.1
</td>
<td class="Rrule Toprule" align="center" valign="top">123-128
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">284-294
</td>
<td class="Rrule Toprule" align="center" valign="top">23,000
</td>
<td class="Rrule Toprule" align="center" valign="top">1.15
</td>
<td class="Rrule Toprule" align="center" valign="top">129-133
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">295-307
</td>
<td class="Rrule Toprule" align="center" valign="top">24,000
</td>
<td class="Rrule Toprule" align="center" valign="top">1.2
</td>
<td class="Rrule Toprule" align="center" valign="top">134-139
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">308-320
</td>
<td class="Rrule Toprule" align="center" valign="top">25,000
</td>
<td class="Rrule Toprule" align="center" valign="top">1.25
</td>
<td class="Rrule Toprule" align="center" valign="top">140-145
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">321-331
</td>
<td class="Rrule Toprule" align="center" valign="top">26,000
</td>
<td class="Rrule Toprule" align="center" valign="top">1.3
</td>
<td class="Rrule Toprule" align="center" valign="top">146-150
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" valign="top">332-344
</td>
<td class="Rrule Toprule" align="center" valign="top">27,000
</td>
<td class="Rrule Toprule" align="center" valign="top">1.35
</td>
<td class="Rrule Toprule" align="center" valign="top">151-156
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="center" valign="top">345-358
</td>
<td class="Rrule Toprule" align="center" valign="top">28,000
</td>
<td class="Rrule Toprule" align="center" valign="top">1.4
</td>
<td class="Rrule Toprule" align="center" valign="top">157-162
</td>
</tr>
</tbody>
</table>
<p>To calculate the volume (mL) of an INNOHEP® 175 anti-Xa IU per kg SC dose for treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>:
</p>
<dl class="Disc">
<dt> 
</dt>
<dd>Patient weight (kg) X 0.00875 mL/kg = volume to be administered (mL) subcutaneously
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-11.2"></a><p></p>
<h2>Administration</h2>
<p class="First">INNOHEP® is a clear, colorless to slightly yellow solution, and as with other parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
</p>
<p>INNOHEP® is administered by SC injection. It must not be administered by intramuscular or intravenous injection.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold">Subcutaneous Injection Technique:</span> Patients should be lying down (supine) or sitting and INNOHEP® administered by deep SC injection.  Administration should be alternated between the left and right anterolateral and left and right posterolateral abdominal wall. The injection site should be varied daily.  The whole length of the needle should be introduced into a skin fold held between the thumb and forefinger; the skin fold should be held throughout the injection. To minimize <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, do not rub the injection site after completion of the injection.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s60"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">INNOHEP® is available in a multiple dose 2 mL vial in the following packages:</p>
<table width="100%">
<col align="left" width="25.000%">
<col align="left" width="75.000%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top">Box of 1</td>
<td align="left" valign="top">2 mL vial (20,000 anti-Xa IU per mL)</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">        NDC 50222-342-08</td>
</tr>
<tr>
<td align="left" valign="top">Box of 10</td>
<td align="left" valign="top">2 mL vials (20,000 anti-Xa IU per mL)</td>
</tr>
<tr class="Last">
<td align="left" valign="top"></td>
<td align="left" valign="top">        NDC 50222-342-53</td>
</tr>
</tbody>
</table>
<p>Store at 25° C (77° F); excursions permitted to 15°-30° C (59°-86° F) [See USP Controlled Room Temperature].</p>
<p>Keep out of the reach of children.</p>
<p>Manufactured by:<br><span class="Bold">LEO Pharmaceutical Products</span><br>DK-2750 Ballerup, Denmark</p>
<p>Distributed by:<br><span class="Bold">LEO Pharma Inc.</span><br>1 Sylvan Way
							<br>Parsippany, NJ 07054
							<br>1-877-494-4536
						</p>
<p><span class="Bold">LEO<span class="Sup">®</span></span></p>
<p>Innohep® is a registered trademark of LEO Pharmaceutical Products.</p>
<table width="100%">
<col align="left" width="50.000%">
<col align="left" width="50.000%">
<tbody class="Headless"><tr class="First Last">
<td align="left" valign="top">May 2010</td>
<td align="right" valign="top"></td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="e03d-11de-851c-0002a5d5c51b"></a><a name="section-13"></a><p></p>
<h1>Package Label - Principal Display Panel – Vial 20,000 anti-xa IU per ml</h1>
<p class="First"><img alt="Innohep Vial 20,000 anti-xa IU per ml" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1513b960-d9d1-11de-8a1e-0002a5d5c51b&amp;name=innohep-05.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INNOHEP 		
					</strong><br><span class="contentTableReg">tinzaparin sodium injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50222-342</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TINZAPARIN SODIUM</strong> (TINZAPARIN) </td>
<td class="formItem">TINZAPARIN SODIUM</td>
<td class="formItem">20000 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM METABISULFITE</strong></td>
<td class="formItem">3.106 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50222-342-08</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50222-342-53</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020484</td>
<td class="formItem">07/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>LEO Pharma Inc.
							(832692615)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>LEO Pharmaceutical Products Ltd. (306218108)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">LEO Pharmaceutical Products Ltd.</td>
<td class="formItem"></td>
<td class="formItem">306218108</td>
<td class="formItem">ANALYSIS, LABEL, MANUFACTURE, PACK</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Wexport Limited</td>
<td class="formItem"></td>
<td class="formItem">986113553</td>
<td class="formItem">ANALYSIS, API MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7974c460-d162-11df-9349-0002a5d5c51b</div>
<div>Set id: 1513b960-d9d1-11de-8a1e-0002a5d5c51b</div>
<div>Version: 5</div>
<div>Effective Time: 20101005</div>
</div>
</div> <div class="DistributorName">LEO Pharma Inc.</div></p>
</body></html>
